Web "E" Paralegal

Peritoneal Mesothelioma is a type of cancer that affects the peritoneum of the human abdominal cavity. Hence, this medical condition is also called as abdominal mesothelioma.

But before seeing more about peritoneal mesothelioma, let us first take a look at the classifications and functions of the peritoneum membrane.

Peritoneum is classified into visceral and parietal peritoneum. The visceral peritoneum envelops the abdominal organs and forms the periphery of the intestinal tract. On the other hand, parietal peritoneum covers the abdominal cavity. The purpose of these layers is to protect the internal organs and to secrete a lubricating fluid that eases the movement of internal organs in the abdominal cavity.

Causes of Peritoneal Mesothelioma

Even though not a definitive explanation, it is widely considered that asbestos is the main cause for peritoneal mesothelioma. According to medical experts, in two ways asbestos dust could reach the intestine lining one through involuntary ingestion during working long hours and days amid asbestos, and secondly, through the lungs while breathing and hence along the lymph nodes to the peritoneal cavity. Either way, it is injurious to the human body, and may invariably lead to this cancerous condition if exposed to for a longer period of time.

Symptoms of Peritoneal Mesothelioma

Peritoneal mesothelioma, like the other forms of mesothelioma, shows a very long latency period and it wont be until 20-30 years since the asbestos-exposure days before any typical symptoms becomes apparent. But by then it will be too late to check the disease or provide any constructive medication or treatment. Further, a delay in diagnosing the disease can happen due to the fact that most of the symptoms of mesothelioma is not-specific and may resemble that of some other common and less serious diseases. For example, the common mesothelioma symptoms include anemia, fever, weight loss, abdominal pain, and bowel obstruction, and it is highly likely that the doctor initially may consider other options than contemplating cancer. Therefore, the patient telling the doctor about any previous asbestos exposure in the first one-to-one interaction itself is very crucial, and that helps the doctor to think of a possible mesothelioma threat even before considering other possibilities.

Treatments

Once the disease has been diagnosed, the doctor recommends the treatments based on several factors such as the extent of the damage, age and medical history of the person and overall health. The traditional treatments for mesothelioma include surgery if the tumor has spread out and is beyond radiation-curable radiation therapy, external and internal radiation, and chemotherapy, which includes using a pill or needle to insert anti-carcinogen drugs into the body.

With the advancement in science and technology, newer treatment techniques have been introduced, and some of it is looking promising as well.

Intraoperative photodynamic therapy is one such newer method that uses special drugs and light to destroy cancer cells. This method is used to study the earlier phases of mesothelioma in the chest.

Further, Immunotherapy is a way of boosting the immunity of ones own body against the spread of cancer. Also, recently, researches have found that Gene Therapy is effective in correcting the faulty genes causing mesothelioma. But these two methods are still in the clinical trials and are yet to be implemented in hospitals.

Even though a wide range of treatments are available for mesothelioma, clinical experiences reveals that none of this alone is capable of checking the disease effectively. Therefore, it is a selected combination of some of these treatments called the “multimodality approach” that is commonly followed and the different modes of treatments to be used are decided by the doctor based on the given medical condition of the patient and his/her age.

Tail Piece Passive exposure to asbestos can also lead to mesothelioma. This happens when asbestos fibers reach the domestic setup through clothes dirties with asbestos dust. Therefore it is advisable that those handling asbestos may change their clothes before returning home or going to any public place.

Mesothelioma stages are categorized in the medical community for evaluative benefit for the physician, the medical institution, participation in clinical trials, and advancements in mesothelioma treatment options. Staging systems are used to define mesothelioma stages; however, mesothelioma stages are far more descriptive for pleural mesothelioma than for peritoneal mesothelioma or pericardial mesothelioma. Mesothelioma staging systems have changed over time. As medical knowledge increases, mesothelioma staging systems advance.

By sectioning a progressive disease into stages, doctors can evaluate mesothelioma treatment options that have been proven successful. By defining mesothelioma stages in a universal staging system, international mesothelioma life expectancy statistics can be gathered. When a staging system gains international acceptance, it contributes greatly to the advancement of mesothelioma treatment options. Grouping similar variables for evaluation is beneficial to developing mesothelioma treatment options for different mesothelioma stages.

In 1976 the Butchart staging system identified four mesothelioma stages for diffuse pleural malignant mesothelioma by location. At stage one, the tumor is in one side of the pleural lining. At stage two, the tumor is malignant and has entered both lungs, and has the potential to spread. In stage three of Butchart?s mesothelioma stages, the tumor has entered the peritoneum (abdomen region), and at stage four, the cancer has spread through the blood stream.

It was simple, thus gained acceptance. However, it fails to address crucial issues. Medical experts suggest it fails to make survival correlations with mesothelioma stages. The Butchart mesothelioma staging system in its originality is obsolete for mesothelioma life expectancy statistics, however other mesothelioma stages have been developed from it, and many cancer institutions modify it for their evaluative purposes.

In the 1980s Chahinian added detailed tumor stages, lymph node stages and metastases stages to the pleural mesothelioma staging system. This staging system is referred to as TNM and is used within elaborative staging systems. In 1990 the UICC (Union Internationale Contre le Cancer) expounded on Chahinian?s mesothelioma stages. The Butchart, Chahinian and UICC mesothelioma staging systems were based on specific institution experience.

In 1999 the Bingham Hospital introduced a pleural mesothelioma surgical staging system in the Journal of Thoracic and Cardiovascular Surgery. The IMIG (International Mesothelioma Interest Group) in a 1995 Journal of Chest from the American College of Chest Physicians proposed international acceptance for a detailed universal staging system. This staging system demands precise tumor location, and is based on TNM and the International Lung Cancer Staging System.

Medical institutions will use the mesothelioma stages and staging system practical for their internal evaluative purposes. But the mesothelioma patient should be aware when discussing mesothelioma life expectancy and prognosis that mesothelioma staging systems differ, and staging systems still undergo scrutiny. No staging system includes all variables for treatment and prognosis. Factors such as tumor subtypes can make a significant difference in prognosis.

In its basic form, mesothelioma has two stages ? localized and advanced. In most staging systems, localized mesothelioma is considered stage one. Stages two through four are advanced mesothelioma stages. Mesothelioma stages are generally defined by location, the severity of the tumor, or surgical needs. The stages of mesothelioma are dependent on the staging system used.

Mesothelioma stages are important considerations in treatment and prognosis. An accepted universal mesothelioma staging system can expedite medical research to find effective mesothelioma treatment options. Advances in clinical research will continue to contribute to the development of defining mesothelioma stages until precise correlations can be made. Until then, staging systems are a universal answer to evaluating mesothelioma treatment.